

Thomas Hielscher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7792321/publications.pdf>

Version: 2024-02-01

193
papers

14,189
citations

38742

50
h-index

21540

114
g-index

196
all docs

196
docs citations

196
times ranked

18320
citing authors

#	ARTICLE	IF	CITATIONS
1	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. <i>Nature</i> , 2012, 482, 226-231.	27.8	2,129
2	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. <i>Cancer Cell</i> , 2012, 22, 425-437.	16.8	1,551
3	Medulloblastoma Comprises Four Distinct Molecular Variants. <i>Journal of Clinical Oncology</i> , 2011, 29, 1408-1414.	1.6	1,131
4	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2017, 18, 682-694.	10.7	586
5	Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma. <i>Cancer Cell</i> , 2011, 20, 143-157.	16.8	494
6	The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation. <i>Cell</i> , 2013, 153, 1064-1079.	28.9	348
7	Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1606-1610.	1.6	329
8	Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. <i>Blood</i> , 2012, 119, 940-948.	1.4	327
9	TERT Promoter Mutations and Risk of Recurrence in Meningioma. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv377.	6.3	283
10	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	10.7	274
11	Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. <i>Oncogene</i> , 2013, 32, 1173-1182.	5.9	252
12	Adult Medulloblastoma Comprises Three Major Molecular Variants. <i>Journal of Clinical Oncology</i> , 2011, 29, 2717-2723.	1.6	215
13	Molecular Staging of Intracranial Ependymoma in Children and Adults. <i>Journal of Clinical Oncology</i> , 2010, 28, 3182-3190.	1.6	210
14	Cell competition is a tumour suppressor mechanism in the thymus. <i>Nature</i> , 2014, 509, 465-470.	27.8	209
15	Progression in Smoldering Myeloma Is Independently Determined by the Chromosomal Abnormalities del(17p), t(4;14), Gain 1q, Hyperdiploidy, and Tumor Load. <i>Journal of Clinical Oncology</i> , 2013, 31, 4325-4332.	1.6	200
16	Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. <i>Acta Neuropathologica</i> , 2011, 122, 231-240.	7.7	195
17	Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. <i>Haematologica</i> , 2011, 96, 87-95.	3.5	188
18	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 125, 373-384.	7.7	169

#	ARTICLE	IF	CITATIONS
19	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	1.6	160
20	Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. <i>Haematologica</i> , 2010, 95, 1150-1157.	3.5	154
21	mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 409-414.	7.1	152
22	Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. <i>Leukemia</i> , 2018, 32, 383-390.	7.2	152
23	FSTL5 Is a Marker of Poor Prognosis in Non-WNT/Non-SHH Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 3852-3861.	1.6	143
24	Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. <i>Acta Neuropathologica</i> , 2010, 120, 253-260.	7.7	129
25	Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. <i>Blood Cancer Journal</i> , 2017, 7, e599-e599.	6.2	124
26	Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. <i>Leukemia</i> , 2015, 29, 1721-1729.	7.2	123
27	Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. <i>Haematologica</i> , 2012, 97, 1757-1760.	3.5	116
28	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. <i>Acta Neuropathologica</i> , 2020, 140, 409-413.	7.7	116
29	Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. <i>Acta Neuropathologica</i> , 2018, 135, 955-963.	7.7	109
30	HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas. <i>Journal of Clinical Investigation</i> , 2013, 123, 2488-2501.	8.2	109
31	Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. <i>Leukemia</i> , 2014, 28, 1902-1908.	7.2	105
32	Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. <i>Blood</i> , 2009, 113, 4331-4340.	1.4	97
33	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. <i>Journal of Clinical Oncology</i> , 2021, 39, 3839-3852.	1.6	93
34	MicroRNA-203 negatively regulates NF- κ B signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer. <i>Molecular Oncology</i> , 2015, 9, 1106-1119.	4.6	82
35	Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. <i>Neuro-Oncology</i> , 2013, 15, 1017-1026.	1.2	78
36	A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. <i>Acta Neuropathologica</i> , 2011, 122, 637-650.	7.7	77

#	ARTICLE	IF	CITATIONS
37	High-Dimensional Cox Models: The Choice of Penalty as Part of the Model Building Process. <i>Biometrical Journal</i> , 2010, 52, 50-69.	1.0	69
38	Integrated molecular characterization of IDH-mutant glioblastomas. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 108-118.	3.2	68
39	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 515-527.	7.7	66
40	Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2014, 28, 174-178.	7.2	66
41	Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma. <i>Carcinogenesis</i> , 2011, 32, 1467-1473.	2.8	64
42	A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR. <i>Epigenetics</i> , 2012, 7, 772-780.	2.7	64
43	Toward an integrated map of genetic interactions in cancer cells. <i>Molecular Systems Biology</i> , 2018, 14, e7656.	7.2	64
44	Role of LIM and SH3 Protein 1 (LASP1) in the Metastatic Dissemination of Medulloblastoma. <i>Cancer Research</i> , 2010, 70, 8003-8014.	0.9	62
45	Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. <i>Haematologica</i> , 2015, 100, 964-969.	3.5	62
46	Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. <i>Annals of Hematology</i> , 2011, 90, 429-439.	1.8	60
47	Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF- κ B activation. <i>Annals of Oncology</i> , 2012, 23, 1795-1802.	1.2	60
48	MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 529-538.	7.7	60
49	Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 1.	6.2	57
50	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. <i>Clinical Cancer Research</i> , 2019, 25, 1851-1866.	7.0	55
51	Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. <i>Cancer</i> , 2011, 117, 2136-2144.	4.1	54
52	GRHL1 Acts as Tumor Suppressor in Neuroblastoma and Is Negatively Regulated by MYCN and HDAC3. <i>Cancer Research</i> , 2014, 74, 2604-2616.	0.9	54
53	Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. <i>Journal of Neurosurgery</i> , 2009, 111, 211-218.	1.6	51
54	The insulin-like growth factor binding proteins 3 and 7 are associated with colorectal cancer and liver metastasis. <i>Cancer Biology and Therapy</i> , 2011, 12, 69-79.	3.4	51

#	ARTICLE	IF	CITATIONS
55	Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival. <i>Cell Death and Disease</i> , 2017, 8, e2635-e2635.	6.3	48
56	Kinome-wide shRNA Screen Identifies the Receptor Tyrosine Kinase AXL as a Key Regulator for Mesenchymal Glioblastoma Stem-like Cells. <i>Stem Cell Reports</i> , 2015, 4, 899-913.	4.8	47
57	Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. <i>Leukemia</i> , 2020, 34, 1853-1865.	7.2	47
58	Molecular driver alterations and their clinical relevance in cancer of unknown primary site. <i>Oncotarget</i> , 2016, 7, 44322-44329.	1.8	47
59	A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma. <i>Haematologica</i> , 2015, 100, 818-825.	3.5	45
60	Asymmetric distribution of TLR3 leads to a polarized immune response in human intestinal epithelial cells. <i>Nature Microbiology</i> , 2020, 5, 181-191.	13.3	45
61	Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients. <i>Haematologica</i> , 2021, 106, 2754-2758.	3.5	45
62	Gene Expression Profiling in Multiple Myeloma – Reporting of Entities, Risk, and Targets in Clinical Routine. <i>Clinical Cancer Research</i> , 2011, 17, 7240-7247.	7.0	43
63	Establishment and application of a novel patient-derived KIAA1549: BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. <i>Oncotarget</i> , 2017, 8, 11460-11479.	1.8	43
64	Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib. <i>Clinical Cancer Research</i> , 2019, 25, 253-265.	7.0	42
65	Nestin Expression Identifies Ependymoma Patients with Poor Outcome. <i>Brain Pathology</i> , 2012, 22, 848-860.	4.1	40
66	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. <i>Leukemia</i> , 2019, 33, 696-709.	7.2	40
67	The renal microenvironment modifies dendritic cell phenotype. <i>Kidney International</i> , 2016, 89, 82-94.	5.2	38
68	Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. <i>Haematologica</i> , 2016, 101, e116-e119.	3.5	37
69	Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLAPsE. <i>Leukemia</i> , 2021, 35, 1134-1144.	7.2	36
70	Fully Automated Pulmonary Lobar Segmentation: Influence of Different Prototype Software Programs onto Quantitative Evaluation of Chronic Obstructive Lung Disease. <i>PLoS ONE</i> , 2016, 11, e0151498.	2.5	35
71	The chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasis. <i>Tumor Biology</i> , 2016, 37, 2461-2471.	1.8	35
72	Cytogenetic intracлонаl heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. <i>Blood Advances</i> , 2018, 2, 2607-2618.	5.2	33

#	ARTICLE	IF	CITATIONS
73	Sequential biphasic changes in claudin1 and claudin4 expression are correlated to colorectal cancer progression and liver metastasis. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 260-272.	3.6	30
74	Fibroblast growth factor receptor 4 gene (<i>FGFR4</i>) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer. <i>International Journal of Cancer</i> , 2012, 131, E586-91.	5.1	29
75	Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism. <i>International Journal of Cancer</i> , 2016, 139, 1776-1787.	5.1	29
76	Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients. <i>Epigenetics</i> , 2016, 11, 61-73.	2.7	29
77	Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study. <i>European Radiology</i> , 2016, 26, 1404-1411.	4.5	28
78	Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma. <i>American Journal of Hematology</i> , 2016, 91, E473-E477.	4.1	27
79	Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology. <i>European Radiology</i> , 2016, 26, 3939-3948.	4.5	27
80	Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial. <i>Bone Marrow Transplantation</i> , 2017, 52, 1194-1198.	2.4	27
81	Prognostic impact of genetic alterations and methylation classes in meningioma. <i>Brain Pathology</i> , 2022, 32, e12970.	4.1	27
82	Risk Factors for Local Recurrence of Large, Flat Colorectal Polyps after Endoscopic Mucosal Resection. <i>Digestion</i> , 2016, 93, 311-317.	2.3	26
83	Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma. <i>Leukemia</i> , 2020, 34, 1192-1196.	7.2	26
84	Patients With Cancer of Unknown Primary. <i>Deutsches Arzteblatt International</i> , 2014, 111, 481-7.	0.9	25
85	Increased microcirculation detected by dynamic contrast-enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma. <i>British Journal of Haematology</i> , 2016, 174, 127-135.	2.5	25
86	Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2018, 2, 1-9.	5.2	25
87	Germline Allele-Specific Expression of DAPK1 in Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2013, 8, e55261.	2.5	24
88	Inhibition of hepatocellular carcinoma growth by blockade of glycosphingolipid synthesis. <i>Oncotarget</i> , 2017, 8, 109201-109216.	1.8	23
89	Oncolytic effects of parvovirus H1 in medulloblastoma are associated with repression of master regulators of early neurogenesis. <i>International Journal of Cancer</i> , 2014, 134, 703-716.	5.1	22
90	Prognostic relevance of miRNA-155 methylation in anaplastic glioma. <i>Oncotarget</i> , 2016, 7, 82028-82045.	1.8	21

#	ARTICLE	IF	CITATIONS
91	T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells. <i>British Journal of Cancer</i> , 2020, 122, 1023-1036.	6.4	20
92	Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity. <i>International Journal of Cancer</i> , 2014, 135, 2380-2386.	5.1	19
93	Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e480.	6.0	19
94	Epigenetic Silencing of DKK3 in Medulloblastoma. <i>International Journal of Molecular Sciences</i> , 2013, 14, 7492-7505.	4.1	18
95	Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients. <i>Journal of Neurology</i> , 2017, 264, 341-349.	3.6	18
96	Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation. <i>Haematologica</i> , 2018, 103, 336-343.	3.5	18
97	Micronucleus formation in human cancer cells is biased by chromosome size. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 392-395.	2.8	17
98	Risk factors associated with progressive lacunar strokes and benefit from dual antiplatelet therapy. <i>European Journal of Neurology</i> , 2020, 27, 817-824.	3.3	17
99	Pathogenetic pathways leading to glioblastoma multiforme: association between gene expressions and resistance to erlotinib. <i>Anticancer Research</i> , 2008, 28, 3729-32.	1.1	17
100	A Robust Alternative to the Schemper-Henderson Estimator of Prediction Error. <i>Biometrics</i> , 2011, 67, 524-535.	1.4	16
101	Caspase-8 modulates physiological and pathological angiogenesis during retina development. <i>Journal of Clinical Investigation</i> , 2019, 129, 5092-5107.	8.2	16
102	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMENSE consortium and meta-analysis. <i>Oncotarget</i> , 2016, 7, 59029-59048.	1.8	16
103	Combining Deep Learning and Radiomics for Automated, Objective, Comprehensive Bone Marrow Characterization From Whole-Body MRI. <i>Investigative Radiology</i> , 2022, 57, 752-763.	6.2	16
104	Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients. <i>Oncotarget</i> , 2018, 9, 25254-25264.	1.8	15
105	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. <i>Brain Pathology</i> , 2016, 26, 506-516.	4.1	14
106	Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. <i>Haematologica</i> , 2016, 101, e485-e487.	3.5	14
107	Longitudinal fluorescence <i>in situ</i> hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. <i>Haematologica</i> , 2017, 102, 1432-1438.	3.5	14
108	Hyperosmolarity impedes the cross-priming competence of dendritic cells in a TRIF-dependent manner. <i>Scientific Reports</i> , 2017, 7, 311.	3.3	14

#	ARTICLE	IF	CITATIONS
109	A PRDX1â€³38± heterodimer amplifies METâ€³driven invasion of <i>IDH</i>â€³wildtype and <i>IDH</i>â€³mutant gliomas. <i>International Journal of Cancer</i> , 2018, 143, 1176-1187.	5.1	14
110	Telomere length, arsenic exposure and risk of basal cell carcinoma of skin. <i>Carcinogenesis</i> , 2019, 40, 715-723.	2.8	14
111	Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. <i>International Journal of Cancer</i> , 2020, 146, 3053-3064.	5.1	14
112	Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma. <i>Blood</i> , 2018, 132, 254-254.	1.4	14
113	Meta-Analysis of Randomized Controlled Trials on Yoga, Psychosocial, and Mindfulness-Based Interventions for Cancer-Related Fatigue: What Intervention Characteristics Are Related to Higher Efficacy?. <i>Cancers</i> , 2022, 14, 2016.	3.7	14
114	A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in <i>BRAF</i>-Driven Pediatric Low-Grade Glioma Cells. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1736-1750.	4.1	13
115	Epidermal growth factor receptor pathway gene expressions and biological response of glioblastoma multiforme cell lines to erlotinib. <i>Anticancer Research</i> , 2008, 28, 3725-8.	1.1	13
116	Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma. <i>Child's Nervous System</i> , 2013, 29, 1253-1262.	1.1	12
117	cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 146, 9-23.	2.9	12
118	The Glycome of Normal and Malignant Plasma Cells. <i>PLoS ONE</i> , 2013, 8, e83719.	2.5	12
119	Riproximinâ€³ activity depends on gene expression and sensitizes PDAC cells to TRAIL. <i>Cancer Biology and Therapy</i> , 2014, 15, 1185-1197.	3.4	11
120	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. <i>Acta Neuropathologica</i> , 2018, 136, 975-978.	7.7	11
121	Susceptibilityâ€³weighted imaging in malignant melanoma brain metastasis. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 1251-1259.	3.4	11
122	Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse. <i>Blood</i> , 2018, 132, 253-253.	1.4	11
123	Findings of Whole Body Computed Tomography Compared to Conventional Skeletal Survey in Patients with Monoclonal Plasma Cell Disorders - a Study of the International Myeloma Working Group. <i>Blood</i> , 2016, 128, 4468-4468.	1.4	11
124	ADCK2 Knockdown Affects the Migration of Melanoma Cells via MYL6. <i>Cancers</i> , 2022, 14, 1071.	3.7	11
125	Metastasis-Related Processes Show Various Degrees of Activation in Different Stages of Pancreatic Cancer Rat Liver Metastasis. <i>Oncology Research and Treatment</i> , 2014, 37, 464-470.	1.2	10
126	Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative. <i>Digestion</i> , 2016, 94, 129-137.	2.3	10

#	ARTICLE	IF	CITATIONS
127	Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018, 32, 2717-2719.	7.2	10
128	Bortezomib-Based Induction Therapy Followed by Autologous Stem Cell Transplantation and Maintenance Therapy with Bortezomib Improves Outcome In Myeloma Patients with Gain 1q21 and t(4;14) - a Subgroup Analysis of the HOVON-65/GMMG-HD4 Trial. <i>Blood</i> , 2010, 116, 305-305.	1.4	10
129	How to evaluate agreement between quantitative measurements. <i>Radiotherapy and Oncology</i> , 2019, 141, 321-326.	0.6	8
130	Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns. <i>Cancers</i> , 2021, 13, 961.	3.7	8
131	Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial. <i>Journal of Hematology and Oncology</i> , 2019, 12, 65.	17.0	7
132	Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 71.	6.2	7
133	Marginal variable screening for survival endpoints. <i>Biometrical Journal</i> , 2020, 62, 610-626.	1.0	7
134	Response Improvement Rather than Response Status after First Autologous Stem Cell Transplantation Is a Significant Prognostic Factor for Survival Benefit from Tandem Compared with Single Transplantation in Multiple Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1280-1287.	2.0	7
135	Comparison of single-scanner single-protocol quantitative ADC measurements to ADC ratios to detect clinically significant prostate cancer. <i>European Journal of Radiology</i> , 2021, 136, 109538.	2.6	7
136	NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasm. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 333-341.	2.8	6
137	SMC3 protein levels impact on karyotype and outcome in acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 795-799.	7.2	6
138	Conditional Alox12b Knockout: Degradation of the Corneocyte Lipid Envelope in a Mouse Model of Autosomal Recessive Congenital Ichthyoses. <i>Journal of Investigative Dermatology</i> , 2020, 140, 249-253.e6.	0.7	6
139	Comparison of Peripheral Zone and Central Gland Volume in Patients Undergoing Intensity-Modulated Radiotherapy. <i>Journal of Computer Assisted Tomography</i> , 2010, 34, 739-745.	0.9	5
140	Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 129, 533-539.	2.9	5
141	Invitation letters increase participation in colorectal cancer screening – results from an observational study. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, 1307-1312.	0.5	5
142	Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma. <i>Leukemia</i> , 2019, 33, 258-261.	7.2	5
143	Clinical outcome of patients with follicular lymphoma and bulky disease after Rituximab+CHOP immunochemotherapy with and without consolidating radiotherapy. <i>European Journal of Haematology</i> , 2010, 85, 11-19.	2.2	4
144	Salvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 27-36.	1.3	4

#	ARTICLE	IF	CITATIONS
145	Influence of Renal Function on Outcome of VAD or Bortezomib, Doxorubicin, Dexamethasone (PAD) Induction Treatment Followed by High-Dose Melphalan (HDM): A Subgroup Analysis From the HOVON-65/GMMG-HD4 Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2010, 116, 2396-2396.	1.4	4
146	The Proportion of Clonal Plasma Cells In the Bone Marrow Analyzed by FISH Rather Than Single Chromosomal Abnormalities Predict Progression From Smoldering to Symptomatic Multiple Myeloma. <i>Blood</i> , 2010, 116, 2950-2950.	1.4	4
147	Multiple behavioral factors are associated with occurrence of large, flat colorectal polyps. <i>International Journal of Colorectal Disease</i> , 2017, 32, 575-582.	2.2	3
148	Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up. <i>Blood</i> , 2019, 134, 3308-3308.	1.4	3
149	GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance â€œ Final Analysis On Induction Therapy. <i>Blood</i> , 2013, 122, 3369-3369.	1.4	3
150	Asymptomatic Multiple Myeloma - Background of Progression, Evolution, and Prognosis. <i>Blood</i> , 2016, 128, 235-235.	1.4	3
151	Bisphosphonate treatment and renal function in 201 myeloma patients undergoing stem cell transplantation. <i>International Journal of Hematology</i> , 2013, 97, 765-772.	1.6	2
152	Transcriptional profiling of dendritic cells matured in different osmolarities. <i>Genomics Data</i> , 2016, 7, 64-66.	1.3	2
153	The effect of gender-specific invitation letters on utilization of colorectal cancer screening. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, 1051-1058.	0.5	2
154	Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2015, 126, 4233-4233.	1.4	2
155	Over 30% of Smoldering Myeloma Patients Have Tumor Cell Bone Marrow Infiltration Patterns Similar to Multiple Myeloma: A Large (n=544) Clinical Study Using Whole-Body MRI.. <i>Blood</i> , 2012, 120, 2911-2911.	1.4	2
156	Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma. <i>American Journal of Hematology</i> , 2012, 87, E68-71.	4.1	1
157	GTF2I Mutation in Thymomas: Independence From Racial-Ethnic Backgrounds. An Indian/German Comparative Study. <i>Pathology and Oncology Research</i> , 2021, 27, 1609858.	1.9	1
158	Quantitative Integrative Prediction of Survival Probability in Multiple Myeloma Using Molecular and Clinical Prognostic Factors in 657 Patients Treated with Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 403-403.	1.4	1
159	Profiling of Oncogenic Signaling in Multiple Myeloma â€œ Association with Biology, Disease Progression and Prognosis. <i>Blood</i> , 2018, 132, 3206-3206.	1.4	1
160	The Chromosomal Abnormalities Del(17p), t(4;14), and +1q21 Predict Progression From Smoldering to Symptomatic Multiple Myeloma. <i>Blood</i> , 2012, 120, 1806-1806.	1.4	1
161	Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma â€œ Subgroup Analysis from the GMMG-MM5 Trial. <i>Blood</i> , 2014, 124, 3475-3475.	1.4	1
162	Signaling Pathway Profiling in Multiple Myeloma. <i>Blood</i> , 2014, 124, 644-644.	1.4	1

#	ARTICLE	IF	CITATIONS
163	Longitudinal Fluorescence in Situ Hybridization at Primary Diagnosis and Relapse Reveals Clonal Evolution after Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2016, 128, 4415-4415.	1.4	1
164	A Gene Expression Based Proliferation Index as Independent Prognostic Factor in Multiple Myeloma.. <i>Blood</i> , 2008, 112, 1667-1667.	1.4	1
165	High-Dose Therapy with Peripheral Blood Stem Cell Transplantation for Patients with Multiple Myeloma: Prognostic Impact of Chromosomal Aberrations and Correlation with the ISS-Score. <i>Blood</i> , 2008, 112, 2708-2708.	1.4	1
166	Appearance of Monoclonal Plasma Cell Diseases in Whole Body MRI in 544 Patients and Correlation with Parameters of Disease Activity. <i>Blood</i> , 2012, 120, 4966-4966.	1.4	1
167	Asymptomatic Multiple Myeloma – Molecular Background of Progression and Prognosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e9-e10.	0.4	0
168	Normalization of serum free light chains during therapy in the MM5 trial predicts prolonged progression free survival and overall survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e208.	0.4	0
169	Impact of cytogenetics at relapse on prognosis and benefit from salvage autologous stem cell transplantation in the GMMG phase III trial ReLApSE. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e286-e287.	0.4	0
170	Impact of Gene Expression Profiling on Diagnosis and Prognostication in Cytogenetically Normal AML.. <i>Blood</i> , 2008, 112, 1487-1487.	1.4	0
171	Clinical Outcome of Patients with Follicular Lymphoma and Bulky Disease After Rituximab-CHOP Immunochemotherapy with and without Consolidating Radiotherapy.. <i>Blood</i> , 2009, 114, 2722-2722.	1.4	0
172	A Clinically Usable Gene Expression Report for Risk Assessment and Identification of Possible Therapeutic Targets in Multiple Myeloma.. <i>Blood</i> , 2009, 114, 1829-1829.	1.4	0
173	Achievement of CR and nCR Before and After First High-Dose Therapy Followed by Autologous Stem Cell Transplantation Is a Major Marker for Long-Term Survival in Multiple Myeloma Patients.. <i>Blood</i> , 2009, 114, 3400-3400.	1.4	0
174	How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Combined with 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Lymphoma (HD2000-Trial).. <i>Blood</i> , 2009, 114, 2687-2687.	1.4	0
175	Cytogenetic Abnormalities and Appearance of Multiple Myeloma in Whole Body-MRI.. <i>Blood</i> , 2009, 114, 4868-4868.	1.4	0
176	Gene Expression Analysis of Independent Data Sets Identifies HBG1 to Be Associated with Outcome in Cytogenetically Normal AML.. <i>Blood</i> , 2009, 114, 2613-2613.	1.4	0
177	Correlation of Serological and MRI-Based Treatment Response to Systemic Chemotherapy In 100 Patients with Multiple Myeloma. <i>Blood</i> , 2010, 116, 2977-2977.	1.4	0
178	Metascoring and Gene Expression Profiling in Clinical Routine in Multiple Myeloma.. <i>Blood</i> , 2011, 118, 3940-3940.	1.4	0
179	Prognostic Significance of the Number of Focal Lesions in Whole Body Magnetic Resonance Imaging Before and After Autologous Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 1812-1812.	1.4	0
180	Combining Information Regarding Chromosomal Aberrations t(4;14), Del(17p13) and the Copy Number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Results From the HOVON-65/GMMG HD4 Trial. <i>Blood</i> , 2011, 118, 332-332.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Impact Of Response Duration and Maintenance Therapy After Autologous Stem Cell Transplantation On Long-Term Survival In Multiple Myeloma Patients. Blood, 2013, 122, 3183-3183.	1.4	0
182	Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial. Blood, 2013, 122, 1897-1897.	1.4	0
183	Influence of Renal Impairment and Genetic Risk Factors on Response to Induction Therapy in the HD4 and MM5 Trials of the GMMG. Blood, 2014, 124, 4777-4777.	1.4	0
184	Impact of Severe Infections during Induction Therapy on Dosage, Response and Survival in Newly Diagnosed Multiple Myeloma - a Subgroup Analysis from the Randomized Phase III Trial GMMG-HD4. Blood, 2015, 126, 3187-3187.	1.4	0
185	Clinical Impact of KMT2C and SPRY4 Expression Levels in Intensively Treated Younger Adult Acute Myeloid Leukemia Patients. Blood, 2016, 128, 1663-1663.	1.4	0
186	Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trial - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal. Blood, 2018, 132, 4485-4485.	1.4	0
187	Modeling of the Epigenome of the Cell-of-Origin Identifies Cancer-Specific DNA Methylation Patterns in CLL. Blood, 2018, 132, 3885-3885.	1.4	0
188	Cohesin Subunit SMC3 Levels Impact on Karyotype and Outcome in Acute Myeloid Leukemia. Blood, 2018, 132, 2786-2786.	1.4	0
189	P-177: Predictive factors for severe infections and early death during novel agent-based induction therapy in newly diagnosed, transplant-eligible myeloma: a multicohort analysis from phase III trials. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S133-S134.	0.4	0
190	P-138: Frequent magnetic resonance imaging partially reduces the development of end organ damage in patients with smoldering myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S110-S111.	0.4	0
191	P-188: Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S140-S141.	0.4	0
192	Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network. Blood, 2021, 138, 3792-3792.	1.4	0
193	P-017: Repeatability and reproducibility of apparent diffusion coefficient measurements of bone marrow in magnetic resonance imaging of multiple myeloma patients. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S48-S49.	0.4	0